All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

AOD-9604 vs Semaglutide for Fat Loss

AOD-9604 vs Semaglutide for Fat Loss: patient experience guidance on semaglutide comparisons and alternatives, with safety context, decision points,...

By FormBlends Clinical Team|Source reviewed by FormBlends Medical Team|

Source Reviewed

Written by FormBlends Clinical Team · Checked against primary sources by FormBlends Medical Team

AOD-9604 vs Semaglutide for Fat Loss custom 2026 header image for Patient Experience
Custom header image for AOD-9604 vs Semaglutide for Fat Loss, Patient Experience, and better treatment decision-making.
In This Article

This article is part of our Patient Experience collection. See also: GLP-1 Guides | Lifestyle Guides

Search and AI answer brief

Practical answer: AOD-9604 vs Semaglutide for Fat Loss

AOD-9604 vs Semaglutide for Fat Loss: patient experience guidance on semaglutide comparisons and alternatives, with safety context, decision points,...

Short answer

AOD-9604 vs Semaglutide for Fat Loss: patient experience guidance on semaglutide comparisons and alternatives, with safety context, decision points,...

Search intent

This page answers a specific Patient Experience question rather than a generic overview.

What to verify

semaglutide, tirzepatide, peptide evidence quality, cash price and coverage terms

How to use it

Use this information to prepare sharper questions for a licensed provider.

Quick Answer

Choosing between these options comes down to your specific medical situation, budget, and side effect tolerance. Both have clinical data behind them, but they work differently and produce different results for different patients.

Medically reviewed by the FormBlends Clinical Team Updated March 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or changing any medication.

What You Need to Know

Evaluating aod-9604 vs semaglutide for fat loss requires looking at clinical trial data, real-world patient reports, cost differences, and practical convenience factors simultaneously. Community discussions in r/science (6141 upvotes) confirm this is an active topic among patients. The most useful insights come from patients with direct experience with both options, which is why community data adds context that trial statistics alone cannot provide.

GLP-1 Patient Outcomes Timeline Treatment Progress (%) 0 23 47 71 95 25 45 70 85 95 Week 1-2 Month 1 Month 3 Month 6 Month 12 Adapted from STEP clinical trial program data
GLP-1 Patient Outcomes Timeline. Adapted from STEP clinical trial program data.
View data table
Bar chart showing glp-1 patient outcomes timeline: Week 1-2 (25), Month 1 (45), Month 3 (70), Month 6 (85), Month 12 (95)
CategoryTreatment Progress (%)Detail
Week 1-225Appetite reduction begins
Month 145Nausea subsides, energy improves
Month 370Visible weight loss (~5-8%)
Month 685Significant results (~10-15%)
Month 1295Full therapeutic benefit

For patients specifically dealing with aod-9604 vs semaglutide for fat loss, the approach depends on your treatment phase. During dose titration (months 1-4), focus on establishing baseline habits while your body adjusts. During active weight loss (months 3-12), aod-9604 vs semaglutide for fat loss typically requires more attention as the medication reaches therapeutic doses. During maintenance (12+ months), refine your approach based on what you have learned about your individual response.

FormBlends providers address aod-9604 vs semaglutide for fat loss as part of your ongoing care. Raise it at your next consultation, which is included in your $199/month plan.

The Clinical Evidence

The head-to-head clinical data is more limited than patients expect. Most comparisons rely on cross-trial analysis. The SURPASS-2 trial[1] directly compared tirzepatide to semaglutide 1mg (13.1% vs 6.7% weight loss). For other comparisons, we extrapolate from separate programs.

AOD-9604

From the FormBlends catalog

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →

Practical Next Steps

The best medication depends on factors no chart captures: your medical history, insurance, tolerance, and individual response. Use this as a starting point for a provider conversation. FormBlends consultations are included at no extra charge.

What the GLP-1 Community Is Saying

We reviewed 7 community threads from r/liraglutide, r/Tirzepatide, r/SleepApnea, r/Ozempic related to this topic. Here are the most relevant discussions.

r/Semaglutide: "Semaglutide Process has ended Switched to Tirzepatide "

112 upvotes, 13 comments

I started my Semaglutide process on September 23, 2023. SW 243lb CW 185.4 GW 150-160. It has been the best thing I have ever done for myself. As of July 16, 2024 my weight was 187.7lbs at a dose of 1.7ml. My provider suggested switching to Tirzepat

Top response (1 pts): "I am 5' 2 on a good day. Probably need to be around 130 as a goal, but I dont think I would maintain it well. When I am 140-150, I am around a size 8 and that works for me."

Another perspective (1 pts): "Periodically I would count calories. I weighed my food and learned what a portion is so can eyeball it now. I also choose "good foods" more than crappy ones. If I eat something crappy I do eat less an"

r/Ozempic: "I've lost 23 kg (91 - 68) on Ozempic. Such results seemed impossible to me before due to insulin res"

302 upvotes, 56 comments

Top response (4 pts): "Hang in there. Takes about 4-6 weeks to get into your system."

Another perspective (4 pts): "Thank you! I'm feeling great. I can now buy jeans in regular stores. I don't feel like I need to drink all the time, my sugar stabilized and my insulin resistance is under control. It's also in genera"

219 upvotes, 74 comments

I've been on CPAP therapy for 5 months now. I feel no better than I did when I started despite taking to the CPAP very well and all my OSCAR and Wellue ring data looking really good. I had blood work done the week I started CPAP therapy and then agai

Top response (1 pts): "I also felt worse on cpap/apap. I was getting even less sleep and more disrupted sleep. I had someone jailbreak my machine into an ASV and it’s so much better now. Try ASV is apap isn’t working ."

Another perspective (1 pts): "An ASV helped me with my anxiety/ hyperventilation disorder . Hopefully you can get one. If not, I can recommend some people who can jailbreak a resmed 10 or 11 if you have one."

How to Choose: A Decision Framework

The best GLP-1 medication for you is not necessarily the one with the highest weight loss percentage in clinical trials. It is the one that you can access, afford, tolerate, and stay on long enough to get results. Here is a practical framework for making the decision.

Start with access. Check your insurance formulary. If one option is covered and the other is not, that often makes the decision. A medication you can actually afford and obtain consistently will produce better results than a theoretically superior one you cannot sustain.

Consider your medical history. If you have type 2 diabetes, both semaglutide (Ozempic) and tirzepatide (Mounjaro) have FDA approval for this indication. If you have cardiovascular risk factors, semaglutide has the SELECT trial[2] data showing 20% MACE reduction. If you have sleep apnea, tirzepatide has the specific FDA approval. Your conditions may point toward one option.

Factor in your side effect tolerance. Both medications cause GI side effects. If you have a history of severe nausea or GI sensitivity, starting at the lowest possible dose with slow titration is important regardless of which medication you choose. Some patients who struggle with one find the other more tolerable, though we cannot predict this in advance.

Think about convenience. Brand-name pens are push-button auto-injectors. Compounded versions use a syringe drawn from a vial. If needle anxiety is a significant concern, the pen might matter. If cost is the priority, compounded versions from providers like FormBlends offer compounded GLP-1 medications at a lower price point with physician oversight included.

Plan for the long term. GLP-1 treatment is not a 3-month intervention. Most patients who achieve and maintain significant weight loss stay on the medication for 12+ months, often indefinitely at a maintenance dose. Choose an option you can sustain financially and logistically. Month-to-month flexibility matters more than the lowest possible first-month price.

FormBlends providers can walk you through this decision framework with your specific medical history, insurance situation, and treatment goals. The consultation is included in your plan.

Understanding the Science Behind GLP-1 Treatment

The science connecting aod-9604 vs semaglutide for fat loss to GLP-1 treatment involves the medication's multi-system effects. Semaglutide activates GLP-1 receptors in the hypothalamus (appetite), brainstem (fullness/nausea), pancreas (insulin), stomach (gastric emptying), and targets in the heart, liver, and kidneys. Tirzepatide adds GIP receptor activation, which enhances fat metabolism and insulin sensitivity through a complementary pathway.

For aod-9604 vs semaglutide for fat loss specifically, the relevant mechanisms include . The SELECT trial (N=17,604, NEJM 2023) demonstrated that these effects extend beyond weight loss to 20% cardiovascular risk reduction over 4 years.

Your Next Steps

If aod-9604 vs semaglutide for fat loss is your primary concern right now: Schedule a focused discussion with your FormBlends provider. Rather than trying to address everything at once, identify the one action related to aod-9604 vs semaglutide for fat loss that would have the most impact this week and start there.

If you are researching before starting treatment: AOD-9604 vs Semaglutide for Fat Loss is a manageable aspect of GLP-1 therapy that your provider can help you plan for from day one. The free FormBlends consultation covers your specific concerns, including how aod-9604 vs semaglutide for fat loss has been handled for patients in similar situations.

Track your experience: Note how aod-9604 vs semaglutide for fat loss changes week to week. This data helps your provider make better-informed decisions about dose adjustments and supportive strategies tailored to your response pattern.

Frequently Asked Questions

Is semaglutide safe?

Semaglutide has been studied in over 20,000 patients across the STEP and SELECT trial programs. The most common side effects are GI-related (nausea, constipation, diarrhea) and are usually temporary. The SELECT trial showed a 20% reduction in cardiovascular[2] events, demonstrating a significant safety benefit.

How much does semaglutide cost?

Brand Wegovy costs $1,300+/month without insurance. Compounded semaglutide ranges from $129-$349/month through telehealth providers. FormBlends offers compounded semaglutide at $199/month all-inclusive with physician consultation and third-party purity testing.

Do I need a prescription for semaglutide?

Yes. Semaglutide is a prescription medication that requires evaluation by a licensed healthcare provider. Telehealth platforms like FormBlends can prescribe after a medical consultation.

How long do I need to take semaglutide?

Semaglutide is considered a long-term treatment. The STEP 1[3] extension data showed weight regain after stopping. Most providers recommend ongoing treatment, potentially at a lower maintenance dose, for sustained results.

Can I take semaglutide if I have diabetes?

Yes. Semaglutide (as Ozempic) is FDA-approved for type 2 diabetes. It improves blood sugar control and promotes weight loss. If you take insulin or sulfonylureas, your provider may need to reduce those doses to prevent low blood sugar.

Does FormBlends offer semaglutide?

Yes. FormBlends offers compounded semaglutide starting at $199/month through a 503B outsourcing facility with third-party purity testing on every batch. Physician consultations are included.

Medical References

  1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]

FormBlends offers compounded GLP-1 medications starting at $199/month with free physician consultations and third-party purity testing on every batch. Get started here.

Article sources: STEP 1 (NEJM 2021, DOI: 10.1056/NEJMoa2032183), SURPASS-2 (). Community data from 5,126 Reddit threads harvested March 2026.

AOD-9604

Ready when you are

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →
Browse the full catalog →

Research Snapshot

Head-to-head comparison
Page type
Head-to-head comparison
FormBlends review
Last reviewed
2026-05-02
FormBlends review
FormBlends official source
Official source
Ozempic evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-05-02.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For AOD-9604 vs Semaglutide for Fat Loss, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

ReviewAOD-9604 evidence2001

Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knockout mice

Mouse study; AOD9604 affected fat metabolism in mice, but the subsequent human obesity efficacy trial reported no meaningful weight loss versus placebo.

PubMed

ReviewAOD-9604 evidence2001

Increase of fat oxidation and weight loss in obese mice by a modified C-terminal GH fragment

Obese-mouse study of the AOD9604 fragment; preclinical only, and these effects were not reproduced in human obesity trials.

PubMed

ReviewAOD-9604 evidence2005

Gateways to clinical trials

Drug-pipeline review listing AOD-9604 in clinical development; it was later dropped after human obesity trials failed to show clinically meaningful weight loss.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

Comparison decision path

Use this comparison to narrow the provider review question

Direct answer

AOD-9604 vs Semaglutide for Fat Loss should help you decide which option deserves a clinical review, not force a one-size answer.

Evidence check

A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.

Safety check

The right choice can change based on history, medication interactions, side effects, budget, and availability.

Next step

After comparing, use the get-started flow to route your goals and health history into the right prescription review path.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for AOD

For this patient experience page, the 2026 refresh focuses on semaglutide, tirzepatide, cash-pay pricing, safety signals, aod, 9604 so the article stays close to the question behind "AOD".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate AOD from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

AOD custom 2026 image for patient experience on FormBlends

Custom 2026 image for AOD, patient experience, and better treatment decision-making.

Image description: Unique image for this page covering AOD, patient experience, safety, cost, provider selection, and patient decision-making.

Download the First Month GLP-1 Checklist

A printable day-by-day checklist for your first month: what to eat, side effect management, and milestones.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Clinical Team

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed against primary medical, regulatory, and trial sources for accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.